Envestnet Asset Management
OTLK icon

Envestnet Asset Management’s Outlook Therapeutics OTLK Stock Holding History

Envestnet Asset Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,724
Closed -$16.5K – 4130
2023
Q3 		$16.5K Buy
3,724
+1,298
+54% +$28.7K ﹤0.01% 3981
2023
Q2 		$84.4K Sell
2,426
-108
-4% -$2.94K ﹤0.01% 3844
2023
Q1 		$55.2K Buy
2,534
+1,154
+84% +$25.8K ﹤0.01% 3845
2022
Q4 		$29.8K Sell
1,380
-48
-3% -$1.04K ﹤0.01% 3902
2022
Q3 		$35K Buy
1,428
+192
+16% +$4.46K ﹤0.01% 3838
2022
Q2 		$25K Buy
1,236
+9
+0.7% +$259 ﹤0.01% 3870
2022
Q1 		$44K Sell
1,227
-596
-33% -$18.6K ﹤0.01% 3869
2021
Q4 		$50K Buy
+1,823
New +$65K ﹤0.01% 3810

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Envestnet Asset Management's OTLK Position: Q4 2023 in Review

Envestnet Asset Management sold out of Outlook Therapeutics (OTLK) in Q4 2023, closing a stake of 3,724 shares — an estimated $16.5K sold.

Envestnet Asset Management first reported a position in OTLK in Q4 2021 and held it in 8 quarters. The position peaked at $84.4K in Q2 2023. 87 funds tracked by Wall St. Rank hold OTLK as of Q4 2023.

  • Envestnet Asset Management reported no remaining Outlook Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 3,724 Outlook Therapeutics shares in Q4 2023, an estimated $16.5K.
  • Envestnet Asset Management first reported a position in Outlook Therapeutics in Q4 2021 and held it in 8 quarters.
  • Envestnet Asset Management's Outlook Therapeutics position peaked at $84.4K in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2023.

Based on Envestnet Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.